Five months after Sanofi backed away from a proposed deal with Maze Therapeutics on a Pompe disease therapy after an antitrust challenge, Shionogi has snapped up the drug.
The Japanese pharma group has licensed Maze’s MZE001 for an upfront fee of $150 million and additional undisclosed milestone payments, adding to its pipeline of rare disease therapies.
